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treatment was based on stage and prognostic score. Other model inputs were 
literature-derived or assumption-based. Costs and QALYs were discounted at a 
3% annual rate. One-way and probabilistic sensitivity analyses examined the rela-
tive impact of model inputs. Results: In the base case scenario 44% of patients 
received ACT using the prognostic test vs. 38% based on SoC. Total costs were 
$131,287 and $125,594 and total QALYs gained were 5.33 and 5.16 for the prognos-
tic test and SoC, respectively. The incremental cost-effectiveness ratio (ICER) for 
the prognostic test was $34,055/QALY gained. One-way sensitivity analyses indi-
cated the probability of receiving ACT for high-risk, stage Ib patients and the ACT 
treatment benefit were the largest drivers of cost-effectiveness. The probabilistic 
sensitivity analysis ICER was $44,196/QALY gained. The prognostic test was cost-
effective in 51.1% of the simulations at a willingness-to-pay threshold of $50,000/
QALY gained. ConClusions: The results of this study suggest that using myPlan 
Lung Cancer to guide ACT decisions is cost-effective compared to a SoC approach 
according to globally accepted thresholds.
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objeCtives: The Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2) is a double-
blind, phase 3 trial that compared Everolimus plus Exemestane (n = 485) versus 
placebo plus Exemestane (n= 239). Postmenauposal women with advanced hormone 
receptor positive breast cancer (ABC) were included in the study. The trial demon-
strated that Everolimus plus Exemestane significantly prolonged progression-free 
survival (PFS). PFS as an outcome measure to compare treatment strategies for ABC 
is incomplete as it fails to account for the quality of life of patients living in that dis-
ease state. To address this issue, researchers can estimate the quality adjusted pro-
gression free survival (QAPFS) of treatments as an effectiveness measure. This study 
aims to estimate the QAPFS of the treatment arms of the BOLERO-2 trial. Methods: 
For each treatment arm of the trial, QAPFS was estimated by multiplying the overall 
health utility weights associated with PFS (taking into consideration disutlities asso-
ciated with the adverse events of treatments) by the corresponding mean PFS time. 
Health utility data were obtained from the literature, while mean PFS times were 
estimated through the survival analysis of the reconstructed individual patient data 
of the BOLERO-2 trial. Results: Progression free survival (robust mean; (95% robust 
confidence interval) was 44.73 weeks (41.03; 48.43) for Evrolimus + Exemestane 
and 22.98 weeks (19.88; 26.08) for Placebo + Exemestane. The QAPFS (robust mean, 
(95% robust confidence interval) for the treatment arms of the trial were respec-
tively 1.67 (1.53; 1.81) for Evrolimus + Exemestane and (0.78; 1.02) for Placebo + 
Exemestane. ConClusions: Using QAPFS as the outcome measure provides a 
better assessment of the benefit induced by the treatment arms of the BOLERO-2 
trial. The benefit of Everolimus + Exemestane over Placebo + Exemestane observed 
in the trial was maintained in this analysis. The estimates obtained as part of our 
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mortality rate at 5 years following treatment as well as recurrence rates following 
chemo-radiation. ConClusions: Cost-utility analysis comparing chemo-radiation 
to cystectomy as primary treatment for MIBC reveals that chemo-radiation is not 
cost-effective when compared to cystectomy.
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objeCtives: To determine the value of different mammography screening modali-
ties from the societal context. Methods: The Wisconsin CISNET breast cancer 
model was adapted to reflect the Canadian context (incidence, resource utilization 
and unit costs (2012 CAN$)). Predictions were made of age-specific breast cancer 
incidence for a 1960 birth cohort of 2,000,000 women for a number of screening sce-
narios varied by age bands (start at 40 or 50 years, end at 69 or 74 years), frequency 
(annual, biennial, triennial) from a societal perspective. Incremental cost-effec-
tiveness and cost-utility analyses were examined for different screening scenarios 
compared to the basecase (biennial 50 to 74 years). A 5% discount rate was used. 
Sensitivity analyses considered screening tool performance, compliance, costs and 
treatments. Results were expressed for 1,000 women alive at age 40 years. Results: 
Our model showed that all annual screening strategies were found to be more 
effective than the basecase. The most aggressive annual screening scenario (40 
to 74 years) saved the lives of 21 more women per 1,000 than the basecase at an 
additional $3,800 per woman. Our model predicted that annual screening from age 
40 to 74 years had a slightly lower incremental ratio compared to annual 40 to 49, 
biennial 50 to 74 years when compared to the basecase. Cost drivers were discount 
rate, screening frequency, utility values, treatment and sensitivity of mammogra-
phy. ConClusions: The greatest single cost contributor in a screening program 
is the mammography itself. The more screens that a women receives in her life, 
the greater the financial cost to society. Because both the life savings and costs rise 
together almost linearly with the number of lifetime screens per women, the deci-
sion on how to screen is mainly related to willingness to pay and avoiding recalling 
too many women for further examinations after positive screens.
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objeCtives: Analyzing the cost-effectiveness of blood cancer-related therapies 
has become more important as expensive drugs have been introduced. This study 
reviewed cost-utility analyses (CUAs) of innovative blood cancer-related interven-
tions and examined the number and methodology of studies and the cost-utility 
ratios. Methods: We analyzed studies related to blood cancers from the Tufts 
Cost-Effectiveness Analysis Registry (www.cearegistry.org), a database including 
over 9,800 CEAs published through 2012. We focused on innovative agents and 
excluded hematopoietic stem cell transplant, symptom management, and sup-
portive care. Studies that met the inclusion criteria were categorized by four cancer 
types (chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), non-
Hodgkin’s lymphoma (NHL), and multiple myeloma (MM)) and nine treatment types 
(α interferon, alemtuzumab, bendamustine, bortezomib, dasatinib, imatinib, leno-
lidomide, rituximab alone or in combination, and thalidomide). Cost-effectiveness 
ratios were stratified by funder and cancer type. Results: Twenty-nine studies 
published from 1996-2012 (including 44 cost-effectiveness ratios) met the inclusion 
criteria. Thirty-one percent were conducted in the US. The majority (62%) used the 
health care payer perspective; 24% used the recommended societal perspective. 
Seventy-six percent were industry-funded. In 21%, economic data were collected 
alongside a clinical trial. Most ratios pertained to NHL (41%) or CML (30%) and to 
treatment with rituximab (43%), α interferon (18%), or imatinib (16%). Across cancers, 
the median ratio was highest for CML ($55,000/QALY) and lowest for NHL ($21,500/
QALY). Median ratios over time were $35,000/QALY (1996-2002), $52,000/QALY (2003-
2006), and $22,000/QALY (2007-2012). A majority of ratios (73%) fell below $50,000/
QALY, and most (86%) fell below $100,000/QALY. The median was lower for indus-
try-funded studies ($26,000/QALY) than others ($33,000/QALY). ConClusions: 
Published CUAs of these blood cancer treatments demonstrate relatively good 
value. While the treatments may have high unit prices, many also seem to confer 
considerable health benefits at reasonable overall costs.
PCN123
Cost-EffECtivENEss of usiNg a ProgNostiC tEst to guidE trEatmENt 
dECisioNs iN Early stagE NoN-small CEll luNg CaNCEr (NsClC)
Stenehjem D1, Bellows B.K.1, Kaldate R.R.2, Jones J.2, Siebert U.3, Brixner D.1
1University of Utah, Salt Lake City, UT, USA, 2Myriad Genetic Laboratories, Inc., Salt Lake City, UT, 
USA, 3UMIT – University for Health Sciences, Medical Informatics and Technology / ONCOTYROL /  
Harvard University, Hall i. T./ Innsbruck / Boston, Austria
objeCtives: Limited guidance exists for health care providers deciding when to 
treat patients with adjuvant chemotherapy (ACT) in early NSCLC. This leads to 
high-risk untreated patients that could benefit, and low-risk patients who could 
avoid the toxicity and cost, from ACT. This study examined the cost-effectiveness 
of the prognostic test myPlan Lung Cancer vs. current standard of care (SoC) in 
directing ACT treatment decisions in stage I/II NSCLC. Methods: A Markov model 
was created to examine costs (2011 US$) and effectiveness (quality-adjusted life-
years [QALYs]), from a US third-party payer perspective over a lifetime horizon. 
Patients were classified as high or low risk based on a prognostic score derived 
from stage and an expression signature based on cell cycle progression. The prob-
ability of receiving ACT was estimated from a physician survey. Benefit of ACT 
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and FISH genetic test costs, re-biopsy cost, probability of progression while on pem-
etrexed treatment and probability of re-biopsy. ConClusions: EML4–ALK genetic 
testing in combination with crizotinib treatment for all NSCLC patients eligible for 
chemotherapy is not economically attractive in the current setting. Lower drug costs 
would be required to make this strategy economically feasible.
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objeCtives: Compare the costs and effectiveness of a nonpharmacologic interven-
tion, mindfulness-based art therapy (MBAT) aimed at psychological stress reduc-
tion for women with breast cancer. Methods: Participants were randomized into 
three groups: MBAT, Usual Breast Cancer Support (BCSG), or Untreated Control (UC). 
The MBAT intervention involved mindfulness-based stress reduction techniques 
along with art therapy. BCSG provided didactic lectures and discussion among par-
ticipants. Each group attended programs for 8 weeks, for 2 ½ hours each week. 
Follow-up was done at 9 weeks. Health care costs due to psychological problems 
were captured in the form of health care utilization, including outpatient calls to 
physicians, outpatient visits, emergency room visits, and inpatient admissions, 
as well as cost of medications. Effectiveness was measured using health utility 
deduced from the Medical Outcomes Study 36-Item Short Form Health Survey (SF-
36). Results: The number of women in each group was: 98 completing MBAT, 93 
completing BCSG, 44 UC. Mean health care costs due to psychological problems 
decreased at 9 weeks in the MBAT group (from $98.96/month to $0.00/month), 
increased in BCSG (from $3.60/month to $32.06/month), and stayed consistent with 
no health care utilization in UC. Medication costs decreased in all 3 groups at 9 
weeks (MBAT: $50.23/month to $6.40/month; BCSG: $48.87/month to $13.69/month; 
UC: $46.80/month to $24.63/month). Health utility (mean,SD) increased at week 9 in 
all groups: MBAT from 0.47(.085) to 0.50(.076); BCSG from 0.50(.086) to 0.52(.084); UC 
from 0.52(.086) to 0.55(.058). ConClusions: All groups experienced similar utility 
improvements at 9 weeks, suggesting that the decision as to whether to choose 
MBAT, BCSG, or UC should be based on costs. However, these data are short-term 
and should be interpreted cautiously since sustained quality of life is important 
to the decision. Findings suggest that MBAT may reduce health care costs due to 
psychological problems but a larger sample is necessary to confirm this.
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objeCtives: To assess the cost-effectiveness of first line metastatic renal cell 
cancer (mRCC) drugs from the perspective of two different economic and clinical 
settings, The Netherlands (NL) and Serbia (SRB). Methods: The research included 
all first line mRCC therapeutics recommended by the European and American 
guidelines: sunitinib, pazopanib, bevacizumab and temsirolimus. Clinical efficacy 
data were extracted from published pivotal and head-to-head studies. Costs were 
described with regards to the treatment protocols of NL and SRB. A Markov model 
was designed to incorporate efficacy and costs data per each therapeutic alterna-
tive. An annual discount rate of 1.5% for health and 4% for costs was applied and 
a health care perspective was taken. Probabilistic sensitivity analysis (PSA) was 
performed to test the uncertainty around the base-case estimate. Results: With 
the incremental cost-effectiveness ratio (ICER) of € 44,512 and € 39,625/QALY in NL 
and SRB respectively, sunitinib was the most cost-effective therapeutic alternative, 
followed by pazopanib, temsirolimus and bevacizumab. Incremental costs were 
comparable in SRB and NL and mainly controlled by the drugs’ price. All estimated 
ICERs appeared lower within Serbian economic surrounding. PSA revealed a wide 
confidence interval around the base-case ICERs highly dependent on potential 
gain in overall survival (OS). ConClusions: The base-case ICERs calculated for NL 
were below the commonly accepted threshold recommended by WHO (three times 
national GDP per capita for QALY or € 95,700/QALY in NL), indicating the relative cost-
effectiveness of examined mRCC drugs. However, none of these pharmaceuticals 
could be regarded as cost-effective under the same criterion in SRB (threshold of 
€ 14,400/QALY). Although between-the-setting variation resulted in lower ICERs in 
SRB, this could not compensate for the sevenfold difference in countries’ incomes. 
Finally, two main parameters that might increase cost-effectiveness of mRCC drugs 
in mid-income countries seem to be the drug prices and their potential benefit in OS.
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objeCtives: Cost-effectiveness of pazopanib versus sunitinib in Egyptian patients 
with metastatic renal cell carcinoma has not yet been established. The aim of the 
present study was to evaluate the cost-effectiveness of pazopanib versus sunitinib 
in Egyptian patients with metastatic renal cell carcinoma over a ten-year period 
from the perspective of the health insurance. Methods: A cohort Markov chain 
model with three health states (first line until progression, progression, and death) 
based on Egyptian clinical practice was derived from published sources. The length 
of a cycle was set at six weeks. The clinical parameters were derived from rand-
omized trial previously published. The quality of life of the health states was derived 
using the available published data. Direct medical costs were obtained from the 
health insurance tariff in Egypt. All costs and effects were discounted at 3.5% annu-
objeCtives: mCRPC is a terminal disease, with a median survival of approximately 
1 to 2 years. The AFFIRM study demonstrated that enzalutamide is highly effica-
cious, prolonging overall survival and progression-free survival compared to placebo 
in patients with mCRPC previously treated with docetaxel-based chemotherapy. 
The purpose of this analysis is to assess from the Canadian perspective the cost-
effectiveness of enzalutamide 160mg once-daily compared with abiraterone acetate 
(AA) (+ prednisone) and intravenous (IV) cabazitaxel in mCRPC patients previously 
treated with docetaxel-based chemotherapy. Methods: A Markov model was 
developed to capture time spent by patients in various health states, including 
progression, progression free survival (PFS) and death. Results were reported as 
incremental costs per additional quality adjusted life-years (QALY) gained over a 
10-year period. Transition probabilities were derived from patient-level data from 
AFFIRM and an indirect treatment comparison from available published literature. 
The base case analysis focused on direct medical costs from the perspective of the 
Canadian Ministry of Health (MoH), with the second analysis focusing on the societal 
perspective. Cost data for 2013, obtained from a variety of sources were reported 
as Canadian Dollars. A 5% discount rate was applied to both costs and patient out-
comes. Multiple sensitivity analyses were undertaken to test the robustness of the 
model Results: From the MoH perspective, enzalutamide had an incremental cost-
utility ratio (ICUR) of $42,325 and $43,105 per additional QALY gained compared to 
AA and cabazitaxel, respectively. Results were similar from the societal perspective. 
Results were robust over a wide range of one-way and probabilistic sensitivity analy-
ses. In greater than 85% of iterations the incremental cost-effectiveness ratio ICER 
was below a willingness-to-pay threshold of $100,000 per QALY for the comparison 
versus either AA or cabazataxel. ConClusions: Enzalutamide is a cost-effective 
treatment compared to AA and cabazitaxel in mCRPC patients previously treated 
with docetaxel-based chemotherapy
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objeCtives: We estimated the incremental cost-utility of newer chromogenic or 
silver in situ hybridization (CISH, SISH) techniques vs. fluorescence-based meth-
ods (FISH) to diagnose human epidermal growth factor receptor-2 positive (HER2+) 
breast cancer (BC) and direct targeted adjuvant trastuzumab using decision-analytic 
modelling. Newer CISH and SISH may be more widely useful in pathology prac-
tice owing to the use of light (vs. fluorescence) microscopy. Methods: A decision 
tree represented 6 alternative test-treat strategies to direct adjuvant trastuzumab 
in HER2+ early-stage BC. The strategies consisted of primary CISH, FISH or SISH 
testing, or, primary immunohistochemistry (IHC) with CISH, FISH or SISH con-
firmation of IHC equivocal results only. We assumed FISH as gold standard, with 
trastuzumab treatment for IHC+ or FISH+. A Markov model of early-stage BC esti-
mated the sequela of treatment based on test results by accounting for true HER2 
status in the lifetime horizon from the payer’s perspective. Treatment effect and test 
accuracy parameters were informed by meta-analyses. Uncertainty was character-
ized using probabilistic sensitivity analyses and cost-effectiveness acceptability 
curves. Results: Primary FISH testing was dominant in the base case, assuming 
20% HER2+ disease prevalence, decreasing costs by a mean of $815 and improving 
outcomes by 0.0022 QALYS compared to the referent strategy of primary IHC with 
FISH confirmation of IHC equivocal results. After HER2+ disease prevalence, results 
were most sensitive to test sensitivity and specificity parameters. Primary FISH, 
CISH or SISH strategies had higher probabilities of being cost-effective than primary 
IHC strategies. ConClusions: Our results suggest that the additional costs of pri-
mary in situ hybridization testing are offset in the long-term by improved health 
outcomes. The significant uncertainty attributed to test accuracy parameters sug-
gests that additional research is needed to determine whether newer CISH or SISH 
can perform equivalently to FISH for HER2 status determination.
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objeCtives: Targeted therapy with ALK inhibitor crizotinib offers significant 
improvement in clinical outcome for treatment of EML4–ALK fusion positive non-
small cell lung cancer (NSCLC) patients. We estimated the cost-effectiveness of 
companion EML4-ALK genetic testing in combination with crizotinib treatment in 
the second-line setting for advanced NSCLC in Ontario. Methods: We performed 
a cost-effectiveness analysis using a Markov model from a Ministry of Health per-
spective and a lifetime horizon. Transition probabilities and mortality rates were 
calculated based on the data of a recent second-line randomized trial of crizotinib 
versus chemotherapy (Shaw et al. New Engl J Med 2013). Costs were obtained from 
OCCI database, public labs and Princess Margaret Hospital. All parameters were 
varied separately in one-way and selected two-way sensitivity analyses. Various 
scenarios to assess the impact of model assumptions about testing and treatment 
were conducted. Results: The use of pemetrexed and docetaxel in ALK-rearranged 
NSCLC, based on our preliminary model, could yield as much as 0.539 QALY and 
0.429 QALY respectively, assuming no crossover from chemotherapy to crizotinib. 
Average costs per patient based on the preliminary model are estimated at CAD 
$19,388 for pemetrexed and $$33,226for docetaxel, with incremental cost-effective-
ness ratios of $333,595/QALY and $125,812/QALY gained respectively. The results of 
the one-way sensitivity analysis indicated that the primary drivers of the ICER were 
the utilities and cost of crizotinib treatment. The model was least sensitive to IHC 
